Loading…

Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice

Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this study is to analyse effectiveness and safety of daclatasvir associated with sofosbuvir with or without...

Full description

Saved in:

Bibliographic Details
Published in:	Revista española de quimioterapia 2019-04, Vol.32 (2), p.137-144
Main Authors:	Margusino-Framiñán, L, Cid-Silva, P, Mena-de-Cea, A, Rodríguez-Osorio, I, Pernas-Souto, B, Delgado-Blanco, M, Pertega-Díaz, S, Martín-Herranz, I, Castro-Iglesias, A
Format:	Article
Language:	English
Subjects:	Original
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites
container_end_page	144
container_issue	2
container_start_page	137
container_title	Revista española de quimioterapia
container_volume	32
creator	Margusino-Framiñán, L Cid-Silva, P Mena-de-Cea, A Rodríguez-Osorio, I Pernas-Souto, B Delgado-Blanco, M Pertega-Díaz, S Martín-Herranz, I Castro-Iglesias, A
description	Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this study is to analyse effectiveness and safety of daclatasvir associated with sofosbuvir with or without ribavirin in G3-HCV infected patients in real clinical practice. An observational, prospective, cohort study over 2.5 years, in G3-HCV infected adult patients, in all fibrosis stages including patients with decompensated cirrhosis. Treatment was a combination of sofosbuvir 400 mg/day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response rates 12 weeks after therapy (SVR12). The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events. A total of 111 patients were enrolled, 32.4% cirrhotics and 29.9% treatment-experienced. The global SVR12 rate was 94.6%, while the SVR12 rate in F3-4 fibrosis stage patients was 90.8% versus 100% in patients with F0-2 fibrosis (p=0.03). In cirrhotic patients, SVR12 was 100% versus 40% depending on whether ribavirin was added or not to daclatasvir/sofosbuvir (p=0.001). No other patient or treatment basal variables influenced the treatment effectiveness. No patient treatment withdrawal secondary to severe adverse events was observed. Daclatasvir/sofosbuvir ± ribavirin is highly effective in G3-HCV infected patients. Advanced degrees of fibrosis significantly decrease the effectiveness of this treatment, which motivates the need for the addition of ribavirin in cirrhotic patients. The regimen was safe and well tolerated.
format	article
fullrecord	<record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6441991</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30761823</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-31e252bfd9e80a60c13bb3a12d1c98b72bafcb5c1d349a2e347854fdca59c5e33</originalsourceid><addsrcrecordid>eNpVkOtKAzEQhYMotlZfQfICq5vLbjd_BCn1AgVB9PcyyU7ayHazbLKVPo5vaooXFAbOYT7mzDBHZMpUVWWqYNUxmeacyUxIribkLIS3PJdCKnZKJiKfl6ziYko-ltaiiW6HHYZAoWtoAItxT72lDZgWIoSdG66Dtz7oMVn67uKG-i_1Y6SD05D6rqOp1tj5uO-RCrrBHqKLLtAFTXwMiR-WYUMPALsYrugzhrGNB0QHhJaa1nXOJNMPkO4yeE5OLLQBL751Rl7vli-Lh2z1dP-4uF1lPS_LmAmGvODaNgqrHMrcMKG1AMYbZlSl51yDNbowrEk_AI5CzqtC2sZAoUyBQszIzVduP-otNiadN0Bb94PbwrCvPbj6P-ncpl77XV1KyZRiKeDyb8Dv5M-zxSepQYL2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice</title><source>PubMed Central</source><creator>Margusino-Framiñán, L ; Cid-Silva, P ; Mena-de-Cea, A ; Rodríguez-Osorio, I ; Pernas-Souto, B ; Delgado-Blanco, M ; Pertega-Díaz, S ; Martín-Herranz, I ; Castro-Iglesias, A</creator><creatorcontrib>Margusino-Framiñán, L ; Cid-Silva, P ; Mena-de-Cea, A ; Rodríguez-Osorio, I ; Pernas-Souto, B ; Delgado-Blanco, M ; Pertega-Díaz, S ; Martín-Herranz, I ; Castro-Iglesias, A</creatorcontrib><description>Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this study is to analyse effectiveness and safety of daclatasvir associated with sofosbuvir with or without ribavirin in G3-HCV infected patients in real clinical practice. An observational, prospective, cohort study over 2.5 years, in G3-HCV infected adult patients, in all fibrosis stages including patients with decompensated cirrhosis. Treatment was a combination of sofosbuvir 400 mg/day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response rates 12 weeks after therapy (SVR12). The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events. A total of 111 patients were enrolled, 32.4% cirrhotics and 29.9% treatment-experienced. The global SVR12 rate was 94.6%, while the SVR12 rate in F3-4 fibrosis stage patients was 90.8% versus 100% in patients with F0-2 fibrosis (p=0.03). In cirrhotic patients, SVR12 was 100% versus 40% depending on whether ribavirin was added or not to daclatasvir/sofosbuvir (p=0.001). No other patient or treatment basal variables influenced the treatment effectiveness. No patient treatment withdrawal secondary to severe adverse events was observed. Daclatasvir/sofosbuvir ± ribavirin is highly effective in G3-HCV infected patients. Advanced degrees of fibrosis significantly decrease the effectiveness of this treatment, which motivates the need for the addition of ribavirin in cirrhotic patients. The regimen was safe and well tolerated.</description><identifier>ISSN: 0214-3429</identifier><identifier>EISSN: 1988-9518</identifier><identifier>PMID: 30761823</identifier><language>eng</language><publisher>Spain: Sociedad Española de Quimioterapia</publisher><subject>Original</subject><ispartof>Revista española de quimioterapia, 2019-04, Vol.32 (2), p.137-144</ispartof><rights>The Author 2019. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</rights><rights>The Author 2019 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441991/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441991/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30761823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Margusino-Framiñán, L</creatorcontrib><creatorcontrib>Cid-Silva, P</creatorcontrib><creatorcontrib>Mena-de-Cea, A</creatorcontrib><creatorcontrib>Rodríguez-Osorio, I</creatorcontrib><creatorcontrib>Pernas-Souto, B</creatorcontrib><creatorcontrib>Delgado-Blanco, M</creatorcontrib><creatorcontrib>Pertega-Díaz, S</creatorcontrib><creatorcontrib>Martín-Herranz, I</creatorcontrib><creatorcontrib>Castro-Iglesias, A</creatorcontrib><title>Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice</title><title>Revista española de quimioterapia</title><addtitle>Rev Esp Quimioter</addtitle><description>Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this study is to analyse effectiveness and safety of daclatasvir associated with sofosbuvir with or without ribavirin in G3-HCV infected patients in real clinical practice. An observational, prospective, cohort study over 2.5 years, in G3-HCV infected adult patients, in all fibrosis stages including patients with decompensated cirrhosis. Treatment was a combination of sofosbuvir 400 mg/day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response rates 12 weeks after therapy (SVR12). The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events. A total of 111 patients were enrolled, 32.4% cirrhotics and 29.9% treatment-experienced. The global SVR12 rate was 94.6%, while the SVR12 rate in F3-4 fibrosis stage patients was 90.8% versus 100% in patients with F0-2 fibrosis (p=0.03). In cirrhotic patients, SVR12 was 100% versus 40% depending on whether ribavirin was added or not to daclatasvir/sofosbuvir (p=0.001). No other patient or treatment basal variables influenced the treatment effectiveness. No patient treatment withdrawal secondary to severe adverse events was observed. Daclatasvir/sofosbuvir ± ribavirin is highly effective in G3-HCV infected patients. Advanced degrees of fibrosis significantly decrease the effectiveness of this treatment, which motivates the need for the addition of ribavirin in cirrhotic patients. The regimen was safe and well tolerated.</description><subject>Original</subject><issn>0214-3429</issn><issn>1988-9518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkOtKAzEQhYMotlZfQfICq5vLbjd_BCn1AgVB9PcyyU7ayHazbLKVPo5vaooXFAbOYT7mzDBHZMpUVWWqYNUxmeacyUxIribkLIS3PJdCKnZKJiKfl6ziYko-ltaiiW6HHYZAoWtoAItxT72lDZgWIoSdG66Dtz7oMVn67uKG-i_1Y6SD05D6rqOp1tj5uO-RCrrBHqKLLtAFTXwMiR-WYUMPALsYrugzhrGNB0QHhJaa1nXOJNMPkO4yeE5OLLQBL751Rl7vli-Lh2z1dP-4uF1lPS_LmAmGvODaNgqrHMrcMKG1AMYbZlSl51yDNbowrEk_AI5CzqtC2sZAoUyBQszIzVduP-otNiadN0Bb94PbwrCvPbj6P-ncpl77XV1KyZRiKeDyb8Dv5M-zxSepQYL2</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Margusino-Framiñán, L</creator><creator>Cid-Silva, P</creator><creator>Mena-de-Cea, A</creator><creator>Rodríguez-Osorio, I</creator><creator>Pernas-Souto, B</creator><creator>Delgado-Blanco, M</creator><creator>Pertega-Díaz, S</creator><creator>Martín-Herranz, I</creator><creator>Castro-Iglesias, A</creator><general>Sociedad Española de Quimioterapia</general><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20190401</creationdate><title>Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice</title><author>Margusino-Framiñán, L ; Cid-Silva, P ; Mena-de-Cea, A ; Rodríguez-Osorio, I ; Pernas-Souto, B ; Delgado-Blanco, M ; Pertega-Díaz, S ; Martín-Herranz, I ; Castro-Iglesias, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-31e252bfd9e80a60c13bb3a12d1c98b72bafcb5c1d349a2e347854fdca59c5e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Margusino-Framiñán, L</creatorcontrib><creatorcontrib>Cid-Silva, P</creatorcontrib><creatorcontrib>Mena-de-Cea, A</creatorcontrib><creatorcontrib>Rodríguez-Osorio, I</creatorcontrib><creatorcontrib>Pernas-Souto, B</creatorcontrib><creatorcontrib>Delgado-Blanco, M</creatorcontrib><creatorcontrib>Pertega-Díaz, S</creatorcontrib><creatorcontrib>Martín-Herranz, I</creatorcontrib><creatorcontrib>Castro-Iglesias, A</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Revista española de quimioterapia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Margusino-Framiñán, L</au><au>Cid-Silva, P</au><au>Mena-de-Cea, A</au><au>Rodríguez-Osorio, I</au><au>Pernas-Souto, B</au><au>Delgado-Blanco, M</au><au>Pertega-Díaz, S</au><au>Martín-Herranz, I</au><au>Castro-Iglesias, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice</atitle><jtitle>Revista española de quimioterapia</jtitle><addtitle>Rev Esp Quimioter</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>32</volume><issue>2</issue><spage>137</spage><epage>144</epage><pages>137-144</pages><issn>0214-3429</issn><eissn>1988-9518</eissn><abstract>Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this study is to analyse effectiveness and safety of daclatasvir associated with sofosbuvir with or without ribavirin in G3-HCV infected patients in real clinical practice. An observational, prospective, cohort study over 2.5 years, in G3-HCV infected adult patients, in all fibrosis stages including patients with decompensated cirrhosis. Treatment was a combination of sofosbuvir 400 mg/day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response rates 12 weeks after therapy (SVR12). The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events. A total of 111 patients were enrolled, 32.4% cirrhotics and 29.9% treatment-experienced. The global SVR12 rate was 94.6%, while the SVR12 rate in F3-4 fibrosis stage patients was 90.8% versus 100% in patients with F0-2 fibrosis (p=0.03). In cirrhotic patients, SVR12 was 100% versus 40% depending on whether ribavirin was added or not to daclatasvir/sofosbuvir (p=0.001). No other patient or treatment basal variables influenced the treatment effectiveness. No patient treatment withdrawal secondary to severe adverse events was observed. Daclatasvir/sofosbuvir ± ribavirin is highly effective in G3-HCV infected patients. Advanced degrees of fibrosis significantly decrease the effectiveness of this treatment, which motivates the need for the addition of ribavirin in cirrhotic patients. The regimen was safe and well tolerated.</abstract><cop>Spain</cop><pub>Sociedad Española de Quimioterapia</pub><pmid>30761823</pmid><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0214-3429
ispartof	Revista española de quimioterapia, 2019-04, Vol.32 (2), p.137-144
issn	0214-3429 1988-9518
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6441991
source	PubMed Central
subjects	Original
title	Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20daclatasvir/sofosbuvir%20with%20or%20without%20ribavirin%20in%20genotype%203%20hepatitis%20C%20virus%20infected%20patients.%20Results%20in%20real%20clinical%20practice&rft.jtitle=Revista%20espa%C3%B1ola%20de%20quimioterapia&rft.au=Margusino-Frami%C3%B1%C3%A1n,%20L&rft.date=2019-04-01&rft.volume=32&rft.issue=2&rft.spage=137&rft.epage=144&rft.pages=137-144&rft.issn=0214-3429&rft.eissn=1988-9518&rft_id=info:doi/&rft_dat=%3Cpubmed%3E30761823%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p266t-31e252bfd9e80a60c13bb3a12d1c98b72bafcb5c1d349a2e347854fdca59c5e33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/30761823&rfr_iscdi=true